Safety endpoint | Early ultrafiltration group (n = 40) | Torasemide plus tolvaptan group (n = 60) | ||
---|---|---|---|---|
Before treatment | After treatment | Before treatment | After treatment | |
Heart rate (beats/min) | 85.25 ± 18.37 | 84.20 ± 14.32 | 82.02 ± 14.65 | 82.72 ± 15.78 |
Systolic blood pressure (mmHg) | 124.98 ± 19.14 | 128.40 ± 19.55 | 128.40 ± 19.55 | 129.12 ± 18.69 |
Diastolic blood pressure (mmHg) | 68.63 ± 11.04 | 67.38 ± 10.07 | 71.93 ± 11.28 | 68.62 ± 10.38 |
Respiratory rate (beats/min) | 20.28 ± 2.89 | 21.68 ± 3.53 | 19.67 ± 2.61 | 20.22 ± 3.29 |
Serum sodium (mmol/L) | 137.12 ± 22.20 | 142.23 ± 4.66 | 141.37 ± 3.85 | 142.50 ± 4.06 |
Serum potassium (mmol/L) | 4.03 ± 0.72 | 4.06 ± 0.54 | 3.83 ± 0.63 | 3.95 ± 0.55 |
Serum creatinine (μmol/L) | 155.70 ± 72.05 | 154.27 ± 88.46 | 128.30 ± 82.66 | 126.57 ± 75.92 |
Access-site ecchymosis (N) | – | 2 | – | – |
Access-site infection (N) | – | 0 | – | – |
Major bleedings (N) | – | 0 | – | – |